No Data
No Data
Scholar Rock Holding Is Maintained at Outperform by BMO Capital
Scholar Rock Holding Is Maintained at Outperform by BMO Capital
BMO Capital Maintains Scholar Rock(SRRK.US) With Buy Rating, Raises Target Price to $31
BMO Capital analyst Etzer Darout maintains $Scholar Rock(SRRK.US)$ with a buy rating, and adjusts the target price from $29 to $31.According to TipRanks data, the analyst has a success rate of 58.7% a
Express News | Scholar Rock Holding Corp : BMO Raises Target Price to $31 From $29
BMO Capital Maintains Scholar Rock(SRRK.US) With Buy Rating, Maintains Target Price $29
BMO Capital analyst Etzer Darout maintains $Scholar Rock(SRRK.US)$ with a buy rating, and maintains the target price at $29.According to TipRanks data, the analyst has a success rate of 58.7% and a to
Truist Financial Maintains Scholar Rock(SRRK.US) With Buy Rating
Truist Financial analyst Srikripa Devarakonda maintains $Scholar Rock(SRRK.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 48.9% and a total average return of 5.5%
Scholar Rock Reports 'Encouraging' Phase 1 Trial Results in Advanced Solid Tumors
Scholar Rock (SRRK) late Monday reported "encouraging" data from a phase 1 proof-of-concept trial of SRK-181 in combination with pembrolizumab in patients with advanced solid tumors. The company said
No Data